A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This two-stage study will examine the effects of a 5 day course of atomoxetine (placebo, 40,
60 or 80 mg/day; Strattera) (a selective NE transporter (NET) inhibitor) on alcohol-elicited
craving and sensitivity to alcohol. The novelty of this study is that of atomoxetine and the
fact that it targets NET, neither of which has heretofore been examined in the context of
alcohol dependence. It is hopeful that this pilot study, of 86 total individuals, will
provide the PI with sufficient preliminary data to submit a subsequent R01 application to
study atomoxetine and the involvement of specific single nucleotide polymorphisms within the
NET gene on alcohol-related phenotypes in alcohol dependent and non-dependent populations.
The long-term objective of this research is to develop more efficacious treatment
interventions for alcohol abuse and dependence.
Hypothesis 1: It is hypothesized that subjects who receive 40, 60 or 80 mg/day of atomoxetine
for 5 days will demonstrate significantly less alcohol-elicited craving than subjects who
receive a placebo.
Hypothesis 2: It is hypothesized that subjects who receive 40, 60 or 80 mg/day of atomoxetine
for 5 days will be less sensitive to the acute effects of alcohol (subjective intoxication)
than subjects who receive a placebo.
Phase:
Phase 1
Details
Lead Sponsor:
University of Colorado, Boulder
Collaborators:
National Center for Research Resources (NCRR) National Institute on Alcohol Abuse and Alcoholism (NIAAA)